Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 420
- 试验地点
- 1
- 主要终点
- Clinical applicability of KRAS mutations
研究概览
简要总结
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
详细描述
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
- Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples.
- Correlation analysis of KRAS mutation results with clinical data.
Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.
- Gene panel composition for pancreatic cancer therapeutic target determination and monitoring.
- A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients.
- Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with pathologically confirmed pancreatic adenocarcinoma.
排除标准
- •Patients disagree with the study.
结局指标
主要结局
Clinical applicability of KRAS mutations
时间窗: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
Discovery of biomarkers through ctDNA panel
时间窗: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.
次要结局
未报告次要终点
研究者
Sang Myung Woo
Chief, Senior Scientist
National Cancer Center, Korea